Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $110.9 million.

  • Crinetics Pharmaceuticals' Cash & Equivalents fell 6504.51% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year decrease of 6504.51%. This contributed to the annual value of $264.5 million for FY2024, which is 37074.58% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Cash & Equivalents is $110.9 million, which was down 6504.51% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Cash & Equivalents registered a high of $1.3 billion during Q1 2025, and its lowest value of $30.9 million during Q3 2022.
  • In the last 5 years, Crinetics Pharmaceuticals' Cash & Equivalents had a median value of $145.5 million in 2022 and averaged $267.9 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Cash & Equivalents plummeted by 8311.44% in 2022, and later soared by 86114.39% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Cash & Equivalents (Quarter) stood at $201.2 million in 2021, then tumbled by 83.11% to $34.0 million in 2022, then skyrocketed by 65.42% to $56.2 million in 2023, then skyrocketed by 370.75% to $264.5 million in 2024, then crashed by 58.08% to $110.9 million in 2025.
  • Its Cash & Equivalents was $110.9 million in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.